Company
Hansoh Pharmaceutical
Hansoh Pharmaceutical has 39 drugs tracked on RxWires: 3 post-market, 1 approved, 5 in Phase 3, 1 in Phase 2/3, 5 in Phase 2, 3 in Phase 1/2, 21 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Inebilizumab | Post-Market | Neuromyelitis Optica Spectrum Disorders |
| Flumatinib | Post-Market | CML, Chronic Phase |
| Tenofovir Amibufenamide（TMF） | Post-Market | Hepatitis B, Chronic |
| GEMCITABINE HYDROCHLORIDE | Approved | |
| HS-10380 | Phase 3 | SCHIZOPHRENIA 1 (Disorder) |
| Linaclotide | Phase 3 | Chronic Idiopathic Constipation |
| HS-10234 | Phase 3 | Chronic HBV Infection |
| HS-20094 Injection | Phase 3 | Type 2 Diabetes |
| Almonertinib | Phase 3 | Lung Cancer |
| Sustained-Release Desvenlafaxine Hydrochloride | Phase 2/3 | Major Depressive Disorder |
| EPO-018B | Phase 2 | Chronic Renal Failure |
| HS-10383 | Phase 2 | Cough |
| Flumatinib mesylate tablet 600 mg qd | Phase 2 | Chronic Myelogenous Leukemia |
| HS-10390 | Phase 2 | Chronic Kidney Disease |
| HS-10342 | Phase 2 | HR+/HER2- Advanced and/or Metastatic Breast Cancer |
| HS-10296 | Phase 1/2 | Nonsmall Cell Lung Cancer |
| HS-10561 | Phase 1/2 | Chronic Spontaneous Urticaria |
| HS-10517 Dose 1 | Phase 1/2 | COVID-19 |
| HS-10582 | Phase 1 | Dyslipidemia |
| HS-20090 | Phase 1 | Healthy |
| Pegol-sihematide injection | Phase 1 | Myelodysplastic Syndromes |
| HS-10352 | Phase 1 | Breast Cancer |
| HS-10541 | Phase 1 | KRAS G12C Mutation Advanced Solid Tumor |
| Aumolertinib；midazolam | Phase 1 | Non Small Cell Lung Cancer |
| HS-10522 | Phase 1 | Healthy Adult |
| HS-20118 | Phase 1 | Psoriasis |
| HS-20136-2 injection | Phase 1 | Healthy |
| HS-20004 | Phase 1 | Healthy |
| Cafusertib Hydrochloride | Phase 1 | Leukemia, Myeloid, Acute |
| HS-10506 | Phase 1 | Healthy |
| Dapagliflozin 10 mg tablets | Phase 1 | Healthy Subjects |
| Azilsartan Trimethylethanolamine | Phase 1 | Health |
| HS-10360 | Phase 1 | Healthy |
| HS-10587 | Phase 1 | MTAP Deletion |
| HS-10504 | Phase 1 | Healthy Participants |
| HS-10241 | Phase 1 | Advanced Non-small Cell Lung Cancer |
| HS-10356 | Phase 1 | Healthy |
| [¹⁴C]HS-10504 | Phase 1 | Healthy Subjects |
| HS-10365 | Phase 1 | NSCLC (advanced Non-small Cell Lung Cancer) |
Latest
No recent events.
Follow Hansoh Pharmaceutical on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.